| 注册
首页|期刊导航|中国临床药学杂志|冰片修饰多柔比星/丹参酮ⅡA磺酸钠双载药纳米粒的制备及其理化性质

冰片修饰多柔比星/丹参酮ⅡA磺酸钠双载药纳米粒的制备及其理化性质

叶晓莉 王丛瑶 何佳 庄建建 尚小广 林能明

中国临床药学杂志2024,Vol.33Issue(1):23-29,7.
中国临床药学杂志2024,Vol.33Issue(1):23-29,7.DOI:10.19577/j.1007-4406.2024.01.004

冰片修饰多柔比星/丹参酮ⅡA磺酸钠双载药纳米粒的制备及其理化性质

Preparation and characterization of doxorubicin-sodium tanshinoneⅡA sulfonate-loaded modifying borneol cationic nanoparticles

叶晓莉 1王丛瑶 2何佳 3庄建建 1尚小广 4林能明1

作者信息

  • 1. 杭州市第一人民医院药学部,杭州 310006
  • 2. 杭州市萧山区第一人民医院药剂科,杭州 311200
  • 3. 树兰(杭州)医院护理部,杭州 310000
  • 4. 杭州师范大学药学院,杭州 311121
  • 折叠

摘要

Abstract

AIM To prepare Doxorubicin-Sodium tanshinone Ⅱ A sulfonate-loaded modifying borneol cationic nanoparticles(BO-DOX/STS-NPs)with brain targeting property.METHODS The BO-DOX/STS-NPs were prepared with the double emulsion solvent evaporation method and were optimized through the orthogonal test according to entrapped efficiency and drug loading of BO-DOX/STS-NPs.RESULTS The optimal conditions for preparation of BO-DOX/STS-NPs were as follows:the mass ratio of drug to PEG2000-PLA was 1∶20,the volume concentration of PVA in the external aqueous phase was 3%,the volume ratio of internal water phase to oil phase was 1∶10,and the volume ratio of oil phase to outer water phase was 1∶10.The mean particle size of the resulted BO-DOX/STS-NPs was(114.75±1.39)nm and Zeta potential was(-6.58±0.02)mV.The average entrapped efficiency was(97.34±0.97)%for DOX and(98.21±0.73)%for STS.The drug-loading capacity was(2.40±0.03)%for DOX and(1.18±0.01)%for STS.The drug release curves for both drugs conformed to the Ritger-Peppas equation model.CONCLUSION An optimized nanoparticle drug delivery system is obtained by the double emulsion method.The optimized nanoparticles have uniform particle size distribution,good stability,high drug loading and sustained release effect.

关键词

多柔比星/丹参酮ⅡA磺酸钠/冰片/纳米粒/正交设计

Key words

doxorubicin/sodium tanshinone ⅡA sulfonate/borneol/nanoparticle/orthogonal design

引用本文复制引用

叶晓莉,王丛瑶,何佳,庄建建,尚小广,林能明..冰片修饰多柔比星/丹参酮ⅡA磺酸钠双载药纳米粒的制备及其理化性质[J].中国临床药学杂志,2024,33(1):23-29,7.

基金项目

杭州市医学重点学科资助(编号:杭卫发[2021]21号) (编号:杭卫发[2021]21号)

浙江省医学重点学科资助(编号:浙卫办[2018]2号) (编号:浙卫办[2018]2号)

浙江省临床肿瘤药理与毒理学研究重点实验室(编号2020E10021),浙江省中医药科技计划项目(编号2014ZA083、2021ZA111) (编号2020E10021)

浙江省卫生健康科技计划项目(编号2021KY865) (编号2021KY865)

杭州市卫生科技计划项目(编号A20210186) (编号A20210186)

浙江省药学会医院药学专项科研基金项目(编号2020ZYY28) (编号2020ZYY28)

中国临床药学杂志

OACSTPCD

1007-4406

访问量0
|
下载量0
段落导航相关论文